Skip to main content
. Author manuscript; available in PMC: 2018 Nov 15.
Published in final edited form as: J Immunol. 2017 Oct 4;199(10):3504–3515. doi: 10.4049/jimmunol.1700289

Figure 8. TCDD decreased PAX5 expression.

Figure 8

Human CD34+ HSPCs were treated with vehicle (VH) or TCDD (0.01, 0.1, 1 or 10 nM) on day 0. Cells were cultured for up to 28 days and harvested at the specified time points. The mRNA levels of PAX5 were assayed by real-time quantitative PCR and were normalized to 18s ribosomal RNA. Data are presented as mean ± SE of triplicate measurements. * p <0.05, **p <0.01, ***p <0.001, compared to the VH using a two way ANOVA with Bonferroni posttest after logarithmic transformation. Data are representative of three independent experiments with similar results.